Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?

Interactive Cardiovascular and Thoracic Surgery

Volumn 12, Issue 5, 2011, Pages 806-810

  Sharif, Sumera ^a   Zahid, Imran ^a   Routledge, Tom ^b   Scarci, Marco ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Diagnosis; Malignant mesothelioma; Positron emission tomography; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; INTERMETHOD COMPARISON; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

BENCHMARKING; BIOPSY; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; FLUORODEOXYGLUCOSE F18; HUMANS; MESOTHELIOMA; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 79956205868     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1510/icvts.2010.255901     Document Type: Article

References (16)

1. Dunning J, Prendergast B, Mackway-Jones K. Towards evidence-based medicine in cardiothoracic surgery: best BETS. Interact CardioVasc Thorac Surg 2003;2:405-409.
2. Mavi A, Basu S, Cermik TF, Urhan M, Bathaii M, Thiruvenkatasamy D, Houseni M, Dadparvar S, Alavi A. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease. Mol Imaging Biol 2009;11:369-378.
3. Yamamoto Y, Kameyama R, Togami T, Kimura N, Ishikawa S, Yamamoto Y, Nishiyama Y. Dual time point FDG PET for evaluation of malignant pleural mesothelioma. Nucl Med Commun 2009;30:25-29.
4. Flores R. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005;49(Suppl 1):S27-S32.
5. Flores RM, Akhurst T, Gonen M, Zakowski M, Dycoco J, Larson SM, Rusch VW. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2006;132:763-768.
6. Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 1999;40:1241-1245.
7. Nowak AK, Francis RJ, Philips MJ, Miliward MJ, van der Schaaf AA, Boucek J, Musk AW, McCoy MJ, Segal A, Robins P, Byrne MJ. A novel prognostic model for malignant meosthelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 2010;16:2409-2417.
8. Ceresoli G, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, Incarbone M, Alloisio M, Santoro A. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with w18Fxfluorodeoxyglucose. J Clin Oncol 2006;24:4587-4593.
9. Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, Price R, Patrikeos AP, Musk AW, Millward MJ. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 2007;48:1449-1458.
10. Nanni C, Castellucci P, Farsad M, Pinto C, Moretti A, Pettinato C, Marengo M, Boschi S, Franchi R, Martoni A, Monetti N, Fanti S. Role of 18F-FDG PET for evaluating malignant pleural mesothelioma. Cancer Biother Radiopharm 2004;19:149-154.
11. Yan TD, Boyer M, Tin MM, Sim J, Kennedy C, McLean J, Bannon PG, McCaughan BC. Prognostic features of long-term survivors after surgical management of malignant pleural mesothelioma. Ann Thorac Surg 2009;87:1552-1557.
12. Wilcox BE, Subramaniam RM, Peller PJ, Aughenbaugh GL, Nichols III FC, Aubry MC, Jett JR. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer 2009;10:244-248.
13. Yildirim H, Metintas M, Entok E, Ak G, Ak I, Dundar E, Erginel S. Clinical value of fluorodeoxyglucose-positron emission tomographyycomputed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease. J Thorac Oncol 2009;4:1480-1484.
14. Lee ST, Ghanem M, Herbertson RA, Berlangieri SU, Byrne AJ, Tabone K, Mitchell P, Knight SR, Feigen M, Scott AM. Prognostic value of 18F-FDG PETyCT in patients with malignant pleural mesothelioma. Mol Imaging Biol 2009;11:473-479.
15. Tan C, Barrington S, Rankin S, Landau D, Pilling J, Spicer J, Cane P, Lang-Lazdunski L. Role of integrated 18-fluorodeoxyglucose positron emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma. J Thorac Oncol 2010;5:385-388.
16. Plathow C, Staab A, Schmaehl A, Aschoff P, Zuna I, Pfannenberg C, Peter SH, Eschmann S, Klopp M. Computed tomography, positron emission tomographyycomputed tomography and magnetic resonance imaging for staging of limited pleural mesothelioma. Invest Radiol 2008;43:737-744.